pyrazines has been researched along with Chromosome Deletion in 20 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 10 (50.00) | 29.6817 |
2010's | 10 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bladé, J; Grosicki, S; Laubach, J; Maloisel, F; Mateos, MV; Min, CK; Orlowski, RZ; Palumbo, A; Polo Zarzuela, M; Prasad, SV; Puchalski, T; Qin, X; Reddy, M; Robak, T; San-Miguel, J; Shpilberg, O; Spencer, A; Tee Goh, Y; Uhlar, C; van de Velde, H; Xie, H | 1 |
Ise, M; Kumagai, K; Sakai, C; Tsujimura, H | 1 |
Hamdy, AA; Neemat, K; Rania, K; Tarek, M | 1 |
Awan, FT; Barrientos, JC; Brown, JR; Byrd, JC; Chaves, J; Covey, T; Devereux, S; Diacovo, TG; Fardis, M; Furman, RR; Ghia, P; Hamdy, A; Harrington, B; Hillmen, P; Huang, J; Izumi, R; Johnson, AJ; Johnson, D; Jones, JA; Kaptein, A; Lannutti, BJ; McGreivy, J; O'Brien, S; Pagel, JM; Rothbaum, W; Schuh, A; Stephens, DM; Wang, X; Wierda, WG; Woyach, J | 1 |
Palumbo, A; Rajkumar, SV | 1 |
Chen, Q; Hunsucker, SA; Kuhn, DJ; Orlowski, M; Orlowski, RZ; Voorhees, PM | 1 |
Kumiega, B; Skotnicki, AB; Wolska-Smoleń, T | 1 |
Kulharya, A; Shah, R; Ustun, C; Yuan, J | 1 |
Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Campion, L; Facon, T; Guerin-Charbonnel, C; Harousseau, JL; Hulin, C; Kolb, B; Leleu, X; Macro, M; Marit, G; Mathiot, C; Minvielle, S; Moreau, P; Roussel, M; Stoppa, AM; Voillat, L; Wetterwald, M | 1 |
Christoulas, D; Dimopoulos, MA; Efstathiou, E; Gavriatopoulou, M; Gkotzamanidou, M; Iakovaki, M; Kastritis, E; Matsouka, C; Migkou, M; Mparmparoussi, D; Roussou, M; Terpos, E | 1 |
An, G; Deng, SH; Li, CW; Li, Q; Liu, XP; Qi, JY; Qiu, LG; Wang, YF; Xu, Y; Zhao, YZ; Zou, DH | 1 |
Bertsch, U; Blau, IW; Derigs, HG; Dührsen, U; Goldschmidt, H; Haenel, M; Hielscher, T; Ho, AD; Hose, D; Jauch, A; Lindemann, W; Lokhorst, HM; Martin, H; Neben, K; Peter, N; Pfreundschuh, M; Raab, MS; Salwender, H; Scheid, C; Schmidt-Wolf, IG; Sonneveld, P; Teschendorf, C; van de Velde, H; van der Holt, B; Weisel, K | 1 |
Chinen, Y; Fuchida, S; Horiike, S; Kiyota, M; Kobayashi, T; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagoshi, H; Nakayama, R; Ohshiro, M; Sakamoto, N; Sasaki, N; Shimazaki, C; Shimura, Y; Taniwaki, M; Uchiyama, H; Yamamoto-Sugitani, M | 1 |
Anderson, K; Hideshima, T; Mitsiades, C; Munshi, N; Richardson, PG; Schlossman, R | 1 |
Harousseau, JL; Moreau, P | 1 |
Chang, H; Qi, X; Reece, D; Stewart, KA; Trieu, Y; Xu, W | 1 |
Ackermann, J; Drach, J; Kaufmann, H; Küenburg, E; Ludwig, H; Odelga, V; Sagaster, V; Wieser, R; Zielinski, C; Zojer, N | 1 |
Anderson, KC; Cowan, JM; Facon, T; Harousseau, JL; Irwin, D; Jagannath, S; Richardson, PG; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
Boral, AL; Esseltine, DL; Jakob, C; Mehta, J; Richardson, P; Sezer, O; Singhal, S; Stadtmauer, E; Vesole, DH | 1 |
Busemann, C; Dölken, G; Kiefer, T; Krüger, WH; Lotze, C; Schüler, F | 1 |
3 review(s) available for pyrazines and Chromosome Deletion
Article | Year |
---|---|
Treatment of newly diagnosed myeloma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Clinical Trials as Topic; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prognosis; Pyrazines; Risk; Thalidomide; Translocation, Genetic; Transplantation Conditioning | 2009 |
Emerging trends in the clinical use of bortezomib in multiple myeloma.
Topics: Antineoplastic Agents; beta 2-Microglobulin; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Therapy; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Transplantation, Autologous | 2005 |
Evolving role of stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Disease-Free Survival; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2005 |
5 trial(s) available for pyrazines and Chromosome Deletion
Article | Year |
---|---|
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 17; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunoglobulin A; Interleukin-6; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate | 2014 |
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Topics: Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Benzamides; Chromosome Deletion; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Headache; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Recurrence | 2016 |
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Cohort Studies; Female; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Smith-Magenis Syndrome; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Young Adult | 2012 |
Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Cohort Studies; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Recurrence; Survival Analysis | 2007 |
Bortezomib-induced tumor lysis syndrome in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Chromosome Deletion; Dexamethasone; Female; Humans; Male; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Treatment Outcome; Tumor Lysis Syndrome | 2006 |
12 other study(ies) available for pyrazines and Chromosome Deletion
Article | Year |
---|---|
Hepatic extramedullary disease in multiple myeloma with 17p deletion.
Topics: Aneuploidy; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Clone Cells; Dexamethasone; Fatal Outcome; Female; Gene Deletion; Genes, p53; Humans; Incidental Findings; Lenalidomide; Liver; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Multiple Primary; Osteolysis; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Tumor Suppressor Protein p53; Uterine Neoplasms | 2014 |
Effect of 13q deletion on IL-6 production in patients with multiple myeloma: a hypothesis may hold true.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Case-Control Studies; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 13; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Interleukin-6; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
Topics: Anti-Inflammatory Agents; Apoptosis; Binding, Competitive; Boronic Acids; Bortezomib; Cells, Cultured; Chromosome Deletion; Chromosomes, Human, Pair 13; Dexamethasone; Dipeptides; Drug Resistance, Neoplasm; Drug Synergism; Endothelium, Vascular; Humans; Immunoblotting; Multiple Myeloma; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Umbilical Veins | 2009 |
[IgA multiple myeloma with adverse prognostic factors--a case report].
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Drug Resistance, Neoplasm; Humans; Immunoglobulin A; Male; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide | 2009 |
Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Clone Cells; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Karyotyping; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplastic Stem Cells; Peripheral Blood Stem Cell Transplantation; Polyploidy; Protease Inhibitors; Pyrazines; Thalidomide; Translocation, Genetic; Transplantation, Autologous | 2010 |
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Chromosome Deletion; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 4; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; France; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Neoadjuvant Therapy; Prospective Studies; Protease Inhibitors; Pyrazines; Time Factors; Translocation, Genetic; Treatment Outcome; Vincristine | 2010 |
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Pyrazines; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
[The significances of 13q14 deletion for development and prognosis of multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 13; Female; Flow Cytometry; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines | 2011 |
Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 13; Dexamethasone; Female; Humans; Male; Metaphase; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome | 2012 |
Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carrier Proteins; CDC2-CDC28 Kinases; Chromosome Deletion; Cyclin-Dependent Kinases; Disease-Free Survival; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Rate; Translocation, Genetic | 2007 |
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.
Topics: Aged; Antineoplastic Agents; Biopsy; Bone Marrow; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytogenetic Analysis; Humans; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Survival Analysis | 2007 |
Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Deletion; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunoglobulin A; Immunoglobulin Light Chains; Leukemia, Plasma Cell; Male; Multiple Myeloma; Pyrazines; Retreatment; Transplantation Chimera; Transplantation, Homologous | 2007 |